Friday, September 04
The U.S. Food and Drug Administration has approved Novartis' gene therapy for patients with a rare muscle disorder, the drugmaker said on Monday.The therapy, branded as Itvisma, was approved for the treatment of spinal muscular atrophy patients of age two years and older who have a confirmed mutation in the survival motor neuron 1 gene.Itvisma contains the same active ingredient as the Swiss drugmaker's older therapy, Zolgensma, which is approved in the U.S. to treat SMA patients less than 2 years of age.The new treatment has a wholesale acquisition cost of $2.59 million, compared with $2.1 million for Zolgensma.Itvisma is the first and only gene replacement therapy available for the broad population, Novartis said."(This) gives patients even more choice, which for any patient is a good th
India's economy likely grew 7.3% in the July-September quarter, according to a Reuters poll of economists, underpinned by strong rural and government expenditure even as private capital spending remained subdued.Household consumption, which accounts for roughly 60% of the economy, strengthened in the previous quarter as rural spending improved on better agricultural output. Urban demand and private investment continued to lag, suggesting uneven growth in Asia's third-largest economy.Government spending, a key driver of growth in recent years, also likely persisted in Q2 of this fiscal year.India remains one of the world's fastest-growing major economies in the face of U.S. President Donald Trump raising tariffs on Indian goods to 50% in August, a move that has contributed to foreign invest
